Curtis et al. performed a large retrospective cohort study in RA to investigate the incidence of ILD in patients receiving TNFi, IL-6 inhibitors or other bDMARDs acting on T-cells or B-cells. This evidence concerns the gene IL6 and rheumatoid arthritis.